Key result
Extended statin use links to debilitating necrotizing autoimmune myopathy successfully diagnosed via antibodies and treated.
Why the study?
Statin-induced necrotizing autoimmune myopathy is a rare side effect of statin use that can cause progressive muscle weakness and requires specific diagnosis.
Case Report (n=1)
This case highlights the importance of recognizing statin-induced necrotizing autoimmune myopathy, a rare but severe complication of statin therapy, which can be diagnosed via specific antibodies.
Anti-HMGCR testing aids SINAM diagnosis in advanced statin myopathy; leaves open optimal management strategies.
Statin-induced necrotizing autoimmune myopathy (SINAM) is a rare side effect of statin use which manifests as progressive muscle weakness. Because statins are a widely prescribed medication for coronary artery disease, hyperlipidemia, and many other diseases, many patients are at risk of developing SINAM or one of the many other statin-induced myopathies. Due to identification of an antibody specific to this disease, we were able to diagnose SINAM in a patient whose symptoms had progressed to the extent that they were debilitating. Our case describes SINAM in a patient undergoing treatment with a statin for an extended period of time, diagnosis of the disease process, treatment, and resolution of symptoms.
No takes yet. Share an insight, caveat, or question.
Dixit et al. (2018) conducted a case report in Statin-induced necrotizing autoimmune myopathy (SINAM) (n=1). Atorvastatin was evaluated on Diagnosis, treatment, and resolution of symptoms. A patient developed debilitating statin-induced necrotizing autoimmune myopathy after extended statin use, which was successfully diagnosed via specific antibodies and resolved with treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: